Lexicon Pharmaceuticals, Inc. Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
285Lexicon Pharmaceuticals's Business Model
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
About Lexicon Pharmaceuticals
Website: https://www.lexpharma.com
CEO (Chief Executive Officer): Mr. Lonnel Coats
IPO date: 2000-04-07
Contact
Country: US
Address: 2445 Technology Forest Boulevard
City: The Woodlands
State: TX
Phone: 281 863 3000
Zip Code: 77381
Other
CIK: 0001062822
ISIN: US5288723027
CUSIP: 528872302
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.